

The correlation and determinants of cost-benefit analysis of measles vaccines among the medical centers providing Expanded Program on Immunization (EPI)

Nimra M*, Hamza Irshad, Muhammad Murtaza Hasnain and Sheikh Muhammad Ishaque

National Institutes of Health, Pakistan

Preface: Measles is a largely contagious viral infection; vaccine- preventable conditions claim the lives of nearly 30 million people each time around the world, including 17 of children under the age of 5.

Methodology: This was a descriptive and cross-sectional disquisition. Retrospective data collection was used. We looked at medical centers that handed EPI administrations.

Results: Around 8 of the youths in the study were set up to have measles, according to the health center's records. There are an undetermined number of measles- infected children. Only 12 of those surveyed had entered the measles vaccine and the vast majority (88) had not entered the shot. According to statistical analysis, the study's r square value is $r = 0.35$, which is considered to be an intermediate direct relationship (Wastage of vaccine and total cost). It illustrates that if there's no system of checks and balances on vaccine waste, it could have an impact on the overall cost of the vaccination. Vaccines destruction shows a positive association with Cure destruction $x_2 = 438.8$ (p-value 0.002). The

breakage of vaccine vial $x_2 = 369.6$ (p-value 0.015), expiration of vaccines $x_2 = 1068$ (p-value 0.006), cold chain conservation $x_2 = 79.99$ (p-value 0.014) and force missing was $x_2 = 2646.9$ (p-value 0.004) showed statistical significance.

Conclusion: The elimination of any complaint would be contributed by the resembling factors one of that includes also fiscal state. In lower time and cost we can vaccinate the number of children and can achieve universal content of immunization.

Keywords: Cost Effectiveness, Epidemiology, Measles, Public Health, Vaccine.

Biography

Nimra M has completed her Doctor of Pharmacy at the age of 23 years from Quaid I Azam University, Pakistan. Later she had done Executive MBA in pharmaceutical marketing. And joined NIH in 2018 as scientific officer and served Biological Production Division as incharge Production and as a faculty of Pharmacology in allied college.

mehak.luck781@gmail.com

Received Date: December 02, 2022; **Accepted Date:** December 05, 2022; **Published Date:** January 31, 2023